Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Glatiramer Acetate (Copaxone) vs Selank
An educational, source-based comparison of Glatiramer Acetate (Copaxone) and Selank — how each peptide works, what it's researched for, and what to know before going deeper.
Synthetic random peptide copolymer for relapsing multiple sclerosis.
Random copolymer of L-glutamic acid, L-lysine, L-alanine, and L-tyrosine that mimics myelin basic protein, shifting T-cell responses toward anti-inflammatory Th2 profile and inducing regulatory T cells.
- Relapsing forms of multiple sclerosis
- Clinically isolated syndrome
- • FDA-approved.
- • Injection-site reactions and transient post-injection chest tightness/flushing possible.
A synthetic analog of the immunomodulatory peptide tuftsin. Research suggests it modulates GABAergic and serotonergic systems and influences expression of brain-derived neurotrophic factor without the sedation or dependence profile of benzodiazepines.
- Generalized anxiety models
- BDNF expression
- Immune modulation
- Memory and learning in rodent models
- • Not FDA-approved.
- • Most studies are Russian clinical literature.
Glatiramer Acetate (Copaxone) vs Selank — Key differences
- Class: Glatiramer Acetate (Copaxone) is classified as Immunomodulator · Neurology, while Selank is Anxiolytic · Nootropic.
- Primary research focus: Glatiramer Acetate (Copaxone) — relapsing forms of multiple sclerosis; Selank — generalized anxiety models.
- Tag: FDA-Approved · Neurology vs Calm · Cognition.